Bilosomes in brain drug delivery

References

• 1. Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 23(6), 1847–1867 (2016).
  Medline CASGoogle Scholar
• 2. Kecman S, Škrbić R, Badnjevic Cengic A et al. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants. Technol. Health Care. 28(3), 325–335 (2020).
  Medline CASGoogle Scholar
• 3. Abdel-moneum R, Abdel-Rashid RS. Bile salt stabilized nanovesicles as a promising drug delivery technology: A general overview and future perspectives. J. Drug. Deliv. Sci. Tech. 104057 (2022).
  Google Scholar
• 4. Pardridge WM. blood–brain barrier delivery. Drug Discov. Today. 12(1-2), 54–61 (2007).
  Medline CASGoogle Scholar
• 5. Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16(1), 1–13 (2004).
  Medline CASGoogle Scholar
• 6. Wang C, Sun J, Chen Q et al. Application of Nanotechnology-Based Products in Stroke. ACS Chem. Neurosci. 14(13), 2405–15 (2023).
  Medline CASGoogle Scholar
• 7. Gvoic M, Vukmirovic S, Al-Salami H et al. Bile acids as novel enhancers of CNS targeting antitumor drugs: A comprehensive review. Pharm. Dev. Technol. 26(6), 617–633 (2021).
  Medline CASGoogle Scholar
• 8. Palmela I, Correia L, Silva RF et al. Hydrophilic bile acids protect human blood–brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study. Front. Neurosci. 9, 80 (2015).
  MedlineGoogle Scholar
• 9. Abbas H, Gad HA, Khattab MA, Mansour M. The Tragedy of Alzheimer's Disease: Towards Better Management via Resveratrol-Loaded Oral Bilosomes. Pharmaceutics. 13(10), 1635 (2021).
  Medline CASGoogle Scholar
• 10. Abbas H, Refai H, El Sayed N et al. Superparamagnetic iron oxide loaded chitosan coated bilosomes for magnetic nose to brain targeting of resveratrol. Int. J. Pharm. 15, 610; 121244 (2021).
  Google Scholar
• 11. Abbas H, El-Feky YA, Al-Sawahli MM et al. Development and optimization of curcumin analog nano-bilosomes using 21.31 full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma: in-vitro evaluation, in-vivo safety assay. Drug Deliv. 29(1), 714–727 (2022).
  Medline CASGoogle Scholar
• 12. Taweel MM, Aboul-Einien MH, Kassem MA, Elkasabgy NA. Intranasal zolmitriptan-loaded bilosomes with extended nasal mucociliary transit time for direct nose to brain delivery. Pharmaceutics. 13(11), 1828 (2021).
  MedlineGoogle Scholar
• 13. Elsheikh MA, El-Feky YA, Al-Sawahli MM et al. A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer's Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes. Pharmaceutics. 14(3), 576 (2022).
  Medline CASGoogle Scholar
• 14. Wu C, Xu Q, Chen X, Liu J. Delivery luteolin with folacin-modified nanoparticle for glioma therapy. Int. J. Nanomedicine. 14, 7515–31 (2019).
  Medline CASGoogle Scholar
• 15. Narayanan VA, Sharma A, P GM, John A. Bilosomes as a Potential Carrier to Enhance Cognitive Effects of Bacopa monnieri Extract on Oral Administration. J. Health Allied Sci. NU 13, 421–430 (2023).
  Google Scholar